Hong Kong · Delayed Price · Currency is HKD Genscript Biotech Earnings Call Transcripts
Fiscal Year 2025
-
Revenue surged 61.4% year-over-year to $959.5 million, with adjusted net profit up 285% to $230.3 million. All segments grew, driven by global expansion, AI-powered innovation, and strong productization, while non-cash losses from Legend Biotech impacted reported net income.
-
Revenue grew 81.9% year-over-year to $519 million, with all segments expanding and adjusted profit from continuing operations reaching $178 million. ProBio saw a 511% revenue jump, driven by Lenovo payments, while Life Science and Bestzyme posted steady growth. Strong cash reserves and global expansion support continued investment and margin resilience.
Fiscal Year 2024
-
Revenue grew 6.1% to $590M, with strong Life Science and Bestzyme growth offsetting ProBio's decline. A $3.2B one-time gain from Legend Biotech deconsolidation drove net profit, while 2025 guidance targets double-digit growth for all segments and stable margins.
-
Revenue rose 43.5% YoY to $561.4M, led by Legend's 156% growth from Carvykti. Life Science and Bestzyme showed solid gains, while ProBio faced headwinds but is recovering. Guidance remains positive for H2, with strong cash positions and ongoing capacity expansions.